Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion type Assertion NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_head.
- NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion description "[Based on published data that show a survival advantage for patients who achieved any cytogenetic response, and high rate of cytogenetic response which we observed in our study we believe that IFN plus AraC regimen could be a front-line therapy for CML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_provenance.
- NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion evidence source_evidence_literature NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_provenance.
- NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion SIO_000772 10985480 NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_provenance.
- NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion wasDerivedFrom befree-2016 NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_provenance.
- NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_assertion wasGeneratedBy ECO_0000203 NP294961.RA5ERtVQe3m8kaGo1B5vaZP9rrq0-bbsMUGKJGjGRDWak130_provenance.